Cargando…

A rare variant of African ancestry activates 8q24 lncRNA hub by modulating cancer associated enhancer

Genetic variation at the 8q24 locus is linked with the greater susceptibility to prostate cancer in men of African ancestry. One such African ancestry specific rare variant, rs72725854 (A>G/T) (~6% allele frequency) has been associated with a ~2-fold increase in prostate cancer risk. However, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Walavalkar, Kaivalya, Saravanan, Bharath, Singh, Anurag Kumar, Jayani, Ranveer Singh, Nair, Ashwin, Farooq, Umer, Islam, Zubairul, Soota, Deepanshu, Mann, Rajat, Shivaprasad, Padubidri V., Freedman, Matthew L., Sabarinathan, Radhakrishnan, Haiman, Christopher A., Notani, Dimple
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368061/
https://www.ncbi.nlm.nih.gov/pubmed/32680982
http://dx.doi.org/10.1038/s41467-020-17325-y
Descripción
Sumario:Genetic variation at the 8q24 locus is linked with the greater susceptibility to prostate cancer in men of African ancestry. One such African ancestry specific rare variant, rs72725854 (A>G/T) (~6% allele frequency) has been associated with a ~2-fold increase in prostate cancer risk. However, the functional relevance of this variant is unknown. Here we show that the variant rs72725854 is present in a prostate cancer-specific enhancer at 8q24 locus. Chromatin-conformation capture and dCas9 mediated enhancer blocking establish a direct regulatory link between this enhancer and lncRNAs PCAT1, PRNCR1 and PVT1. The risk allele (‘T’) is associated with higher expression of PCAT1, PVT1 and c-myc in prostate tumors. Further, enhancer with the risk allele gains response to androgen stimulation by recruiting the transcription factor SPDEF whereas, non-risk alleles remain non-responsive. Elevated expression of these lncRNAs and c-myc in risk allele carriers may explain their greater susceptibility to prostate cancer.